BBCP, BLTE and CWH have been added to the Zacks Rank #5 (Strong Sell) List on August 4, 2025.

PBR's second-quarter results may reflect stronger oil and gas output, but maintenance losses can weigh on earnings.

Tyson Foods (TSN) came out with quarterly earnings of $0.91 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.87 per share a year ago.

Lindblad Expeditions (LIND) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.48 per share a year ago.

ArcelorMittal has been named as a Top 5 dividend paying metals and mining stock, according to Dividend Channel, which published its weekly ''DividendRank'' report. The report noted that among metals and mining companies, MT shares displayed both attractive valuation metrics and strong profitability metrics.

The EV maker's board granted 96 million shares of restricted stock to its CEO after a judge struck down earlier pay packages.

Medicus Pharma (NASDAQ:MDCX) has agreed a non-binding memorandum of understanding with Boston-based Helix Nanotechnologies to develop a new generation of vaccines that remain stable at room temperature. The two companies plan to combine HelixNano's technology, which uses messenger ribonucleic acid (mRNA) to instruct the immune system how to fight off infectious diseases, with Medicus's method of delivering vaccines using dissolvable microneedle patches.

A strategy of selecting stocks based on rapid revenue growth has outperformed the broad market over the decades.

MP Materials has transformed from a speculative miner to a strategic U.S. asset, driven by major deals with the DoD and Apple. Options flow, GEX/DEX structure, and dark pool data all point to bullish institutional positioning ahead of earnings, with key levels at $65 and $85. The DoD's equity stake and Apple's commitment de-risk MP's business model, providing long-term demand and margin visibility, making it a rerating story.

AEM beats Q2 earnings and revenue estimates as surging gold prices offset lower production and higher costs.

XRAY's Imaging strength and SureSmile growth might have lifted Q2 performance, but Byte's drag and macro pressures likely clouded the top-line momentum.

MEMPHIS, Tenn.--(BUSINESS WIRE)--The 2025 FedEx St. Jude Championship begins this week as the PGA TOUR and FedEx bring 70 of the world's best golfers to the 68th PGA TOUR stop in Memphis while showcasing the impact of these decades of philanthropic support. Since 1970, the Memphis PGA Tour stop has raised more than $80 million to benefit St. Jude Children's Research Hospital® and children with cancer and other life-threatening diseases. “The FedEx St. Jude Championship is more than a golf tourn.

A pair of billionaires kick off Morning Trade Live's stock coverage for the week. Tesla's (TSLA) board approved a 96 million share packaged for Elon Musk worth approximately $30 billion.

RTX's Q2 results reaffirm its global leadership, record $236B backlog, and robust performance across all business segments, justifying an upgrade to 'buy'. Despite high valuation multiples and market expectations of perfection, RTX's quality, growth, and revenue visibility support a long-term core portfolio position. Risks include valuation compression and operational challenges, but RTX's resilience and adaptability underpin its appeal for disciplined, patient investors.

Tesla's board has signed off a $29bn (£21.8bn) share award to Elon Musk after a court blocked an earlier package worth almost double that sum.

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. MRNA stock has plummeted over 70% in the past year, reflecting investor concerns about ongoing losses and limited COVID vaccine demand. Despite recent approval of mNEXSPIRE, guidance suggests heavy 2025 losses, with management focused on downsizing and cost control.

FIVN posts record Q2 revenue, boosts AI growth, and trades at a steep valuation discount, making it a mid-cap AI standout.

CVE tops Q2 EPS estimates with cost cuts but posts revenue decline and weaker segment contributions.

ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.

ACB's global medical cannabis momentum stays strong, but near-term regulatory headwinds might have limited Q1 revenue upside.